These data provide a strong clinical rationale for the combination of chidamide, azacitidine, cytarabine, aclarubicin and granulocyte colony-stimulating factor (CACAG) in combination with VEN for the treatment of R/R AML. Here, CSF3 is linked to acute myeloid leukemia.